Aprea TherapeuticsAPRE -1.67%30 OCF Yield % is -120.07 as of Jun. 25, 2026. GuruFocus rates APRE with a GF Score™ of 30/100. The stock has 1 warning sign investors should review. Among 1,418 Biotechnology companies, Aprea Therapeutics ranks worse than 91.96% on this metric.
OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Aprea Therapeutics OCF Yield % Related Terms
Aprea Therapeutics OCF Yield % Historical Data
* Premium members only.
The historical data trend for Aprea Therapeutics's OCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Aprea Therapeutics's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aprea Therapeutics OCF Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Aprea Therapeutics's OCF Yield % distribution charts can be found below:
* The bar in red indicates where Aprea Therapeutics's OCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aprea Therapeutics (APRE) has a OCF Yield % of -120.07 as of Jun. 25, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Aprea Therapeutics and its competitors. According to the industry distribution chart, Aprea Therapeutics ranks #1304 out of 1418 companies in the Biotechnology industry, placing it in the top 92%.
Is Aprea Therapeutics' OCF Yield % too high?
Aprea Therapeutics' current OCF Yield % is -120.07. Based on the distribution chart, Aprea Therapeutics ranks #1304 out of 1418 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Aprea Therapeutics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Aprea Therapeutics' OCF Yield % compare to JUNS and KAPA?
According to the Biotechnology industry distribution chart, Aprea Therapeutics ranks #1304 out of 1418 companies for OCF Yield %. This places Aprea Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Biotechnology company?
A good OCF Yield % depends on the Biotechnology industry context. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Aprea Therapeutics and its competitors. Aprea Therapeutics's current OCF Yield % is -120.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aprea Therapeutics stock overvalued right now?
Aprea Therapeutics (APRE) has a current OCF Yield % of -120.07. The current OCF Yield % is -120.07. Aprea Therapeutics' overall GF Score™ is 30/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For Aprea Therapeutics (APRE), the current OCF Yield % is -120.07 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Aprea Therapeutics Inc is a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers. It develops small molecule inhibitors designed to exploit genetic mutations in cancer to widen the therapeutic window and is intended to make treatments more effective at destroying cancer cells while sparing healthy tissue. The company's pipeline of clinical and preclinical programs includes APR-1051, a WEE1 inhibitor; ATRN-119 (Mosipasertib), an oral small molecule inhibitor of ataxia telangiectasia and Rad3-related, or ATR; and an early-stage program, APR-1602. These candidates are being developed for broad applications in cancer treatment.
30GF Score
Get the complete analysis for APRE
OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
APRE has been successfully added to your 
